Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, United States.
Department of Pharmacological Science and Research, School of Pharmacy, Marshall University, Huntington, WV 25755, United States.
Cell Signal. 2020 Aug;72:109651. doi: 10.1016/j.cellsig.2020.109651. Epub 2020 Apr 23.
Src family kinases (SFKs) play a crucial role in the regulation of multiple cellular pathways, including mitochondrial oxidative phosphorylation (OXPHOS). Aberrant activities of one of the most predominant SFKs, c-Src, was identified as a fundamental cause for dysfunctional cell signaling and implicated in cancer development and metastasis, especially in human hepatocellular carcinoma (HCC). Recent work in our laboratory revealed that c-Src is implicated in the regulation of mitochondrial energy metabolism in cancer. In this study, we investigated the effect of c-Src expression on mitochondrial energy metabolism by examining changes in the expression and activities of OXPHOS complexes in liver cancer biopsies and cell lines. An increased expression of c-Src was correlated with an impaired expression of nuclear- and mitochondrial-encoded subunits of OXPHOS complexes I and IV, respectively, in metastatic biopsies and cell lines. Additionally, we observed a similar association between high c-Src and reduced OXPHOS complex expression and activity in mouse embryonic fibroblast (MEF) cell lines. Interestingly, the inhibition of c-Src kinase activity with the SFK inhibitor PP2 and c-Src siRNA stimulated the expression of complex I and IV subunits and increased their enzymatic activities in both cancer and normal cells. Evidence provided in this study reveals that c-Src impairs the expression and function of mitochondrial OXPHOS complexes, resulting in a significant defect in mitochondrial energy metabolism, which can be a contributing factor to the development and progression of liver cancer. Furthermore, our findings strongly suggest that SFK inhibitors should be used in the treatment of HCC and other cancers with aberrant c-Src kinase activity to improve mitochondrial energy metabolism.
Src 家族激酶(SFKs)在调节多种细胞途径中起着至关重要的作用,包括线粒体氧化磷酸化(OXPHOS)。SFKs 中最主要的激酶之一 c-Src 的异常活性被确定为细胞信号转导功能障碍的根本原因,并与癌症的发展和转移有关,尤其是在人类肝细胞癌(HCC)中。我们实验室最近的工作表明,c-Src 参与调节癌症中线粒体的能量代谢。在这项研究中,我们通过检查肝癌活检和细胞系中 OXPHOS 复合物的表达和活性变化,研究了 c-Src 表达对线粒体能量代谢的影响。c-Src 的高表达与转移性活检和细胞系中线粒体编码的 OXPHOS 复合物 I 和 IV 的核编码亚基的表达分别受损相关。此外,我们还观察到在高 c-Src 和降低的 OXPHOS 复合物表达和活性之间存在类似的关联,这种关联存在于小鼠胚胎成纤维细胞(MEF)细胞系中。有趣的是,SFK 抑制剂 PP2 和 c-Src siRNA 抑制 c-Src 激酶活性可刺激复合物 I 和 IV 亚基的表达,并增加它们在癌症和正常细胞中的酶活性。本研究提供的证据表明,c-Src 损害了线粒体 OXPHOS 复合物的表达和功能,导致线粒体能量代谢的显著缺陷,这可能是肝癌及其他具有异常 c-Src 激酶活性的癌症发展和进展的一个促成因素。此外,我们的发现强烈表明,应在治疗 HCC 和其他具有异常 c-Src 激酶活性的癌症时使用 SFK 抑制剂,以改善线粒体能量代谢。